Arbutus Biopharma Stock Quote ABUS - Stock Price, News, Charts, Message Board, Trades

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Arbutus Biopharma Corporation (ABUS) Quote

Arbutus Biopharma Corporation (ABUS)

3.425

-0.035

( -1.01% )

Updated: 11:36:18

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

3.425

Bid

3.42

Ask

3.43

Volume

115,237

3.365 Day's Range 3.48

1.98 52 Week Range 4.725

Market Cap

Previous Close

3.46

Open

3.47

Last Trade

Last Trade Time

11:37:30

Financial Volume

$ 394,406

VWAP

3.4226

Average Volume (3m)

1,041,576

Shares Outstanding

189,491,685

Dividend Yield

-

PE Ratio

-8.82

Earnings Per Share (EPS)

-0.38

Revenue

18.14M

Net Profit

-72.85M

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid na... Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.tekmirapharm.com

Headquarters

Burnaby, British Columbia, Can

Founded

-

Arbutus Biopharma Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ABUS. The last closing price for Arbutus Biopharma was $3.46. Over the last year, Arbutus Biopharma shares have traded in a share price range of $ 1.98 to $ 4.725.

Arbutus Biopharma currently has 189,491,685 shares outstanding. The market capitalization of Arbutus Biopharma is $655.64 million. Arbutus Biopharma has a price to earnings ratio (PE ratio) of -8.82.

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Believes Now Is the Logical Time for Arbutus to Pursue a License and Collaboration Agreement With a Strategic Partner and Explore All Options for HBV Portfolio Urges Arbutus to Commit to No...

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

Form 8-K - Current report

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arbutus to Present at Jefferies London Healthcare Conference

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.025	-0.724637681159	3.45	3.52	3.365	558686	3.44874083	CS
4	-0.435	-11.2694300518	3.86	3.96	3.365	942397	3.60106089	CS
12	-1.1013	-24.3311313877	4.5263	4.61	3.365	1041576	3.9313697	CS
26	0.065	1.93452380952	3.36	4.725	2.915	1045127	3.7611022	CS
52	1.415	70.3980099502	2.01	4.725	1.98	1059103	3.25921645	CS
156	-0.625	-15.4320987654	4.05	4.725	1.69	1230586	3.04423958	CS
260	1.845	116.772151899	1.58	9	0.88	2132477	3.71451678	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTNTCheetah Net Supply Chain Service Inc	$ 5.35 (186.10%)	98.93M
ZJKZJK Industrial Company Ltd	$ 11.925 (88.09%)	12.98M
CTORCitius Oncology Inc	$ 1.70 (66.67%)	88.69M
GWAVGreenwave Technology Solutions Inc	$ 0.584 (60.00%)	269.46M
JANXJanux Therapeutics Inc	$ 63.112 (57.07%)	4.27M
REVBRevelation Biosciences Inc	$ 0.593 (-37.57%)	2.44M
OMEXOdyssey Marine Exploration Inc	$ 0.4752 (-36.23%)	2.88M
SNTISenti Biosciences Inc	$ 6.865 (-31.35%)	5.37M
XCURExicure Inc	$ 15.7384 (-29.42%)	288.02k
STSSSharps Technology Inc	$ 2.37 (-29.33%)	149.31k
GWAVGreenwave Technology Solutions Inc	$ 0.5828 (59.67%)	269.5M
SMCISuper Micro Computer Inc	$ 41.10 (-2.14%)	139.94M
CTNTCheetah Net Supply Chain Service Inc	$ 5.35 (186.10%)	98.93M
CHRSCoherus BioSciences Inc	$ 2.04 (48.91%)	92.88M
CTORCitius Oncology Inc	$ 1.70 (66.67%)	88.69M

db7

db7 3 weeks ago

nice new Blackrock 13F: https://stocktwits.com/bs010101/message/592459944

db7

db7 3 weeks ago

2 days to AASLD...

mick

mick 1 month ago

db7

db7 2 months ago

2 late breakers for AASLD: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-multiple-abstracts-highlighting-imdusiran-data

mick

mick 2 months ago

https://www.stockscores.com/charts/charts/?ticker=ABUS

mick

mick 3 months ago

ABUS
Arbutus Biopharma Corporation
4.5488
0.0388 (0.86%)
Volume: 1,579,948
Day Range: 4.39 - 4.56
Last Trade Time: 7:46:00 PM EDT

db7

db7 3 months ago

breaking out; dare i say 'someone' knows 'something'(?)

db7

db7 3 months ago

ARBUTUS PHARMA CORP. et al v. PFIZER INC. et al "Please take notice that an in-person Markman Hearing is hereby scheduled for 12/18/2024 at 10:30AM in Trenton- Courtroom 4W. So Ordered by Judge Zahid N. Quraishi on 9/3/2024. (kas)"

db7

db7 3 months ago

Monksdream

Monksdream 3 months ago

DewDiligence

DewDiligence 4 months ago

ABUS pares pipeline–reduces workforce 40%:

https://finance.yahoo.com/news/arbutus-reports-second-quarter-2024-113000099.html

The company’s will focus on clinical development of Imdusiran regimens for HBV, but will terminate research on new HBV compounds.

Oddly (for the reason mentioned at the bottom of #msg-174556022), ABUS opted to retain its oral PD-1 program.

Rockurstocks

Rockurstocks 4 months ago

Not for long! $ABUS$

Monksdream

Monksdream 4 months ago

mick

mick 5 months ago

ABUS
Arbutus Biopharma Corporation
3.645
-0.135 (-3.57%)
Volume: 449,700
Day Range: 3.645 - 3.845
Last Trade Time: 2:29:04 PM EDT

Monksdream

Monksdream 5 months ago

ABUS new 52/week high

db7

db7 5 months ago

db7

db7 6 months ago

https://www.sec.gov/Archives/edgar/data/1447028/000089542124000390/ArbutusABUS.txt

db7

db7 6 months ago

New Presentation: https://investor.arbutusbio.com/static-files/f33bde13-92b8-48c4-a40e-36cf6dd25852

db7

db7 6 months ago

Poster for EASL https://www.arbutusbio.com/wp-content/uploads/2024/06/WED-371-Yuen-et-al-AB-729-201-IFN-poster-EASL-2024_FINAL.pdf

mick

mick 6 months ago

ABUS
Arbutus Biopharma Corporation
3.341
-0.019 (-0.57%)
Volume: 534,638
Day Range: 3.30 - 3.385
Last Trade Time: 12:14:00 PM EDT
Delayed by 15 minutes

db7

db7 6 months ago

EASL June 6-8th:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-present-imdusiran-data-easl-congress-2024

"
HBsAg = LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of subjects who received 4 or 6 doses of imdusiran plus 24 weeks of IFN
"

db7

db7 6 months ago

Arbutus is waking up a little following yesterday's Motion to Dismiss with Acuitas:
https://www.law360.com/ip/articles/1839088/judge-tosses-acuitas-covid-biotech-ip-suit-

other important events of late include:

1) company stating they have stopped their ATM and don't see a need to use it the rest of this year

2) the Markman order against Moderna that went in their favor:
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-announces-claim-construction-ruling-its

3) Activist becoming involved:
https://www.morningstar.com/news/business-wire/20240517970994/whitefort-capital-publishes-open-letter-to-arbutus-biopharma-shareholders-outlining-paths-to-maximize-value

db7

db7 7 months ago

issue here, now, might be too many open $3 calls? will mm's hold her under....

db7

db7 7 months ago

mgmt killed this stock with that ATM; imo, used in a suspicious manner... ie: they put a lid on her on the markman order release at $3ish .. WHY would you do that? They could have raised same money at double the price

MWM

MWM 7 months ago

db7

db7 7 months ago

https://www.businesswire.com/news/home/20240517970994/en/

db7

db7 7 months ago

from Whitefort's 13D filed today: "The Reporting Persons have conveyed their view to the Issuer’s Board of Directors (the “Board”) that the current market price of the Shares does not reflect the Issuer’s intrinsic value. The Reporting Persons have requested that the Board immediately terminate the Issuer’s ATM program and explore all strategic options for the Issuer’s hepatitis B virus (HBV) portfolio. The Reporting Persons hope to continue to work constructively and collaboratively with the Board on these critical initiatives and intend to actively engage with shareholders and others regarding their views."

Monksdream

Monksdream 7 months ago

mick

mick 7 months ago

TWTR
Twitter Inc
53.70
0.00 (0.00%)
Volume:

Monksdream

Monksdream 8 months ago

db7

db7 8 months ago

looking a little better today; i guess it's going to be slow and steady and not the rocket on markman day like i hoped. i think this is looking really good med-long term on the litigation from after that markman ruling

also, looking forward to EASL in june

mick

mick 8 months ago

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

mick

mick 8 months ago

ABUS
Arbutus Biopharma Corporation
3.00
0.08 (2.74%)
Volume: 1,253,240
Day Range: 2.86 - 3.11
Bid: 2.99
Ask: 3.00
Last Trade Time: 9:56:51 AM EDT
Total Trades: 3,890

mick

mick 8 months ago

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 8 months ago

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 8 months ago

Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

mick

mick 8 months ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04/04/2024 08:30:49 AM
Arbutus to Participate in Two Upcoming Investor Conferences
03/08/2024 07:30:00 AM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
03/05/2024 04:48:49 PM

Paullee

Paullee 8 months ago

07:15 AM EDT, 04/04/2024 (MT Newswires) -- A US court ruled against Moderna (MRNA) in a patent infringement case by Arbutus (ABUS) over its COVID-19 vaccines, Reuters reported Wednesday.

US District Judge Mitchell Goldberg interpreted the patents in ways that favored Arbutus' case and hurt Moderna', Reuters reported.

Arbutus sued Moderna in 2022, claiming the company's COVID-19 vaccine impinged on its patents for lipid nanoparticles that shield the vaccine's mRNA from the body's immune system.

Moderna and Arbutus did not immediately respond to MT Newswires' requests for comment.

MWM

MWM 8 months ago

Watching all 3 stocks. $ABUS is kind of moving...

db7

db7 8 months ago

was going to take all '3' to explode imo..

MWM

MWM 8 months ago

Yes, I'm trying to read it myself

db7

db7 8 months ago

decision is out; looks like arbutus won '2' and moderna '1' .. please confirm

db7

db7 9 months ago

https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/

Desert dweller

Desert dweller 9 months ago

My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.

Desert dweller

Desert dweller 10 months ago

Handle on twitter is @DesertDweller93

MWM

MWM 10 months ago

Great post!

What’s your handle on Twitter?

Desert dweller

Desert dweller 10 months ago

I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.

MWM

MWM 10 months ago

A couple bad headlines for MRNA of late. Here is one of todays...

Moderna’s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizer’s

db7

db7 10 months ago

yes, quite the drop yesterday and today on mrna... g/l!

MWM

MWM 10 months ago

Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...

Arbutus Biopharma

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions